Astrazeneca (AZN) Profit After Tax (2009 - 2026)

Astrazeneca's Profit After Tax history runs 18 years deep, the most recent figure standing at $2.5 billion for Q2 2026.

• In Q2 2026, Profit After Tax rose 2.45% year-over-year to $2.5 billion; the TTM figure through Jun 2026 stood at $10.5 billion (up 25.91% YoY), while the FY2025 annual figure was $10.2 billion, up 45.33% from the prior year.
• Profit After Tax for Q2 2026 stood at $2.5 billion, down from $3.1 billion in the prior quarter.
• The five-year high for Profit After Tax was $5.0 billion in Q4 2023, with the low at $360.0 million in Q2 2022.
• The 5-year median for Profit After Tax is $1.9 billion (2023), against an average of $2.0 billion.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax jumped 597.58% in 2022, then plunged 70.01% in 2024.
• Astrazeneca's Profit After Tax stood at $902.0 million in 2022, then jumped by 454.55% to $5.0 billion in 2023, then slumped by 70.01% to $1.5 billion in 2024, then surged by 55.27% to $2.3 billion in 2025, then gained by 7.69% to $2.5 billion in 2026.
• Business Quant data shows AZN's Profit After Tax at $2.5 billion in Q2 2026, $3.1 billion in Q1 2026, and $2.3 billion in Q4 2025.